Peer-Reviewed Scientific Paper Confirms Safety of Water Treated by BioLargo's Advanced Oxidation System
Back to Newsroom
Mentioned in this Article

Peer-Reviewed Scientific Paper Confirms Safety of Water Treated by BioLargo's Advanced Oxidation System

Monday, June 21, 2021 8:30 AM
Share this article now
Topic:
Company Update

Study demonstrates AOS generates less disinfection by-products than common wastewater treatment technologies

WESTMINSTER, CA / ACCESSWIRE / June 21, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced the publication of a peer-reviewed scientific paper about its patented energy-efficient water disinfection technology the Advanced Oxidation System (AOS). The paper, which focused on quantifying the disinfection by-products generated by the AOS, represents a critical milestone in the commercialization of BioLargo's innovative water treatment technology.

BioLargo's ground-breaking AOS technology is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies such as UV and ozone-based systems. Significantly, the AOS removes pharmaceutical micropollutants from water to provide added value across diverse water treatment applications, including municipal wastewater treatment.

The study, led by the laboratory of Dr. Susana Kimura-Hara at the University of Calgary, assessed the disinfection by-products (DBPs) generated by the BioLargo AOS. The paper concluded that the levels of DBPs generated by the AOS were comparable to those found in ordinary tap water.

The paper's abstract and summary can be accessed here: https://www.sciencedirect.com/science/article/abs/pii/S0043135421005388

As all water treatment technologies generate DBPs, the quantity and relative safety of disinfection byproducts generated by a given water treatment technology is an important consideration for customers deciding which technology to select for their needs. The results of this study therefore represent an important milestone for the AOS, which has a municipal wastewater treatment demonstration pilot underway near Montréal, Québec, and is currently being readied for commercial trials.

This study corroborates the results of another peer-reviewed paper published earlier this year that showed the AOS does not increase the toxicity of treated water. Notably, that study also showed the AOS to be capable of negating the negative effects of two hard-to-treat micropollutants, with the paper's author Dr. Greg Goss calling the AOS, "a major technical breakthrough for the treatment of micropollutants."

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.

BioLargo, Inc.
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions